Established in 2003, the Institute of Bioengineering and Nanotechnology (IBN) is the world’s first bioengineering and nanotechnology research institute. The institute’s research activities are focused on health and medical technologies, cultivated meat technologies, antimicrobials and targeted therapeutics delivery. Our multi-disciplinary research at the interface of science (biology and chemistry) and engineering has been application-driven, delivering innovative solutions for industry and the community, particularly in the areas of national needs like cancers and infectious diseases, and more recently, food and nutrition.
IBN has contributed significantly to the development of Singapore’s research capabilities through scientific breakthroughs and innovations, establishing several industrial, clinical and academic collaborations. The institute has published over 1,400 papers in leading scientific journals and accounts for a significant proportion of the Biomedical Research Council’s active patent portfolio. To date, IBN’s technologies have been translated and commercialised through more than 10 spin-off companies like Lucence and InvitroCue.
A leader in innovative bioengineering and nanotechnology research
IBN spearheads innovative research to meet societal needs, improving healthcare and quality of life.
As a multi-disciplinary institute that conducts cutting-edge research in the convergence of science (biology and chemistry) and engineering disciplines, IBN develops disruptive technologies or novel engineering solutions for biomedical/bio-based challenges.
A*STAR Outstanding Publications Award 2009-14, 2016-17, and 2019
A*STAR Patent Power Award 2009-10, 2017 and 2019
Singapore HEALTH Award (Platinum) 2012, (Gold) 2008 and 2010
BCA Green Mark Award 2013 (Gold) and 2017 (Gold and Goldplus)